PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
-10%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$4.14B
AUM Growth
+$4.14B
(-27%)
Cap. Flow
-$722M
Cap. Flow
% of AUM
-17.44%
Top 10 Holdings %
Top 10 Hldgs %
47.31%
Holding
128
New
20
Increased
20
Reduced
31
Closed
18
Top Buys
| 1 |
Iovance Biotherapeutics
IOVA
|
$53.4M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$45.3M |
| 3 |
Immatics
IMTX
|
$40.7M |
| 4 |
CTNM
Contineum Therapeutics
CTNM
|
$27.6M |
| 5 |
Merus
MRUS
|
$17.8M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$149M |
| 2 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$146M |
| 3 |
Medtronic
MDT
|
$73.9M |
| 4 |
Sarepta Therapeutics
SRPT
|
$68.1M |
| 5 |
Axsome Therapeutics
AXSM
|
$52M |
Sector Composition
| 1 | Healthcare | 99.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Protagonist Therapeutics
PTGX
$3.67B
| $44M | 1.06% | 1,268,735 +274,412 | +28% | +$9.51M |
|
27
Solid Biosciences
SLDB
$427M
| $39.2M | 0.94% | 6,906,646 | – | – |
|
28
Celcuity
CELC
$2.17B
| $38.7M | 0.93% | 2,362,279 | – | – |
|
|
29
Medtronic
MDT
$119B
| $38.6M | 0.93% | 490,665 -938,898 | -66% | -$73.9M |
|
30
Viking Therapeutics
VKTX
$3.04B
| $38.2M | 0.92% | 721,377 -272,721 | -27% | -$14.5M |
|
31
Applied Therapeutics
APLT
$71M
| $37.4M | 0.9% | 8,005,000 | – | – |
|
|
32
Axsome Therapeutics
AXSM
$6.05B
| $37M | 0.89% | 459,111 -646,230 | -58% | -$52M |
|
|
CNTA
33
Centessa Pharmaceuticals
CNTA
$2.25B
| $35.5M | 0.86% | 3,933,307 +850,000 | +28% | +$7.68M |
|
34
Tarsus Pharmaceuticals
TARS
$2.47B
| $35.2M | 0.85% | 1,296,416 | – | – |
|
|
VRNA
35
Verona Pharma
VRNA
$9.16B
| $35.2M | 0.85% | 2,433,725 -1,327,851 | -35% | -$19.2M |
|
36
Akero Therapeutics
AKRO
$3.74B
| $35.2M | 0.85% | 1,499,897 +112,426 | +8% | +$2.64M |
|
37
Edgewise Therapeutics
EWTX
$1.51B
| $33.4M | 0.81% | 1,856,417 -463,229 | -20% | -$8.34M |
|
38
Acrivon Therapeutics
ACRV
$42.2M
| $31.1M | 0.75% | 5,360,858 +2,353,000 | +78% | +$13.6M |
|
39
Praxis Precision Medicines
PRAX
$958M
| $31M | 0.75% | 750,230 -71,359 | -9% | -$2.95M |
|
40
ADMA Biologics
ADMA
$4.12B
| $31M | 0.75% | 2,771,000 -3,662,369 | -57% | -$40.9M |
|
41
BridgeBio Pharma
BBIO
$9.89B
| $30.8M | 0.74% | 1,215,346 -196,687 | -14% | -$4.98M |
|
42
Aldeyra Therapeutics
ALDX
$351M
| $30.7M | 0.74% | 9,275,851 +682,265 | +8% | +$2.26M |
|
43
Nautilus Biotechnolgy
NAUT
$85.9M
| $29.5M | 0.71% | 12,594,211 | – | – |
|
|
CTNM
44
Contineum Therapeutics
CTNM
$293M
| $27.6M | 0.66% | +1,566,668 | New | +$27.6M |
|
45
Intuitive Surgical
ISRG
$170B
| $27.5M | 0.66% | 61,800 -40,000 | -39% | -$17.8M |
|
46
Arvinas
ARVN
$568M
| $27.4M | 0.66% | 1,027,749 -208,854 | -17% | -$5.56M |
|
47
Rocket Pharmaceuticals
RCKT
$354M
| $26.8M | 0.65% | 1,246,597 -554,471 | -31% | -$11.9M |
|
48
Disc Medicine
IRON
$2.07B
| $24.9M | 0.6% | 553,437 -386,429 | -41% | -$17.4M |
|
49
LivaNova
LIVN
$3.08B
| $24.3M | 0.59% | 444,000 +145,000 | +48% | +$7.95M |
|
50
CG Oncology
CGON
$2.04B
| $23.2M | 0.56% | 733,695 -570,410 | -44% | -$18M |
|